Noticias y eventos de Veraxa Biotech AG (VRXA)VRXAVeraxa Biotech AG

Veraxa Biotech and Secarna Collaborate on Antibody Oligonucleotide Development

Veraxa Biotech and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates for the treatment of autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate sourced by combining both parties' technologies and expertise demonstrated greater potency compared to the equivalent unconjugated, naked oligonucleotide, underlining the future therapeutic potential of the approach. Encouraged by these results, both parties are now discussing the next steps in this alliance.

Veraxa Biotech Advances VXA-222 Bispecific ADC Program

Veraxa Biotech (VRXA) announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb (OABI). The program is moving into its next collaboration phase with OmniAb's discovery work concluded. VXA-222 utilizes an "AND-gate" logic to address two different target antigens present on solid tumors with one molecule. Established in May 2025, the alliance and joint discovery collaboration brought together OmniAb's suite of transgenic antibody discovery solutions and screening technologies with Veraxa Biotech's antibody drug conjugate linker technology and conjugation expertise to support next-generation therapeutic discovery. Under the terms of the May 2025 agreement, Veraxa Biotech initiated a novel bsADC program addressing two attractive target molecules in cancer medicine. The company utilized OmniAb's suite of transgenic antibody discovery solutions, including OmniClic, a common light-chain transgenic chicken developed to facilitate the generation of bispecific antibodies, to source high-quality human antibody leads, which are naturally optimized through in vivo affinity maturation. Veraxa Biotech will subsequently establish the bsADC lead candidate by applying its proprietary linker technology and conjugation routine and will be responsible for in vitro and in vivo validation. Veraxa Biotech holds exclusive rights to develop and commercialize products incorporating the OmniAb-derived antibodies under the collaboration, with OmniAb entitled to a share of specified revenue generated from those products.

Veraxa Biotech Appoints Christoph Erkel as Chief Scientific Officer

Veraxa Biotech announced the appointment of Christoph Erkel as chief scientific officer, effective immediately. Christoph Erkel, previously VP of research and development at Veraxa Biotech, will apply his management expertise in R&D to direct and accelerate development of the company's proprietary BiTAC platform technologies.